Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04206553 |
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid |
COMPLETED | PHASE2/PHASE3 |
| NCT03926377 |
Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid |
COMPLETED | PHASE4 |
